ATRIVA Antiviral pipeline anticipated progress to 2020
The development and patenting of proprietary dosage forms in conjunction with the already existing IP on usage of MEK inhibitors fighting influenza provides excellent USPs for ATRIVA’s ATR-002 drug candidate.
You may click on each of the projects to get more details once these have been disclosed.
ATRIVA’s lead project is treatment of Influenza in patients at risk for developing severe complications due to comorbidities.
The proprietary dosage form of our lead compound ATR-002 is in its final development stage.It is anticipated that clinical development of ATR-002 can start in second half of 2018 with a Phase 1 study in healthy volunteers, ensuring the safety and favorable PK profile of the compound.
A proof-of-principle for the treatment of Influenza with ATR-002 will be established using a human virus challenge model, allowing to substantiate the antiviral properties of ATR-002 in humans.
ATR-005 Bacterial Co-Infection in Influenza
In patients with acute Influenza infection, especially patients with comorbidities, bacterial co-infections play a major role for morbidity and mortality.
Especially bacterial pneumonia occurring shortly after the acute Influenza infection imposes a major threat to patients. Our compound ATR-002 showed promising bacteriostatic properties, next to the antiviral properties, in preclinical models.
The effect on bacterial co-infections will be further evaluated to substantiate the current preclinical findings of bacteriostatic properties of ATR-002 in multi-resistant bacterial strains.